Omalizumab for management of hypersensitivity reactions to anticancer drugs.

Piyush GroverMatthew KrummenacherTimothy LoyAnna K NowakMichaela Lucas

Published in: Internal medicine journal (2024)

Hypersensitivity reactions to anticancer drugs include treatment-limiting toxicity. Standard drug desensitisation offers temporary tolerance and hence requires repetition. We used omalizumab, an anti-immunoglobulin E antibody, to overcome immediate and delayed hypersensitivity reactions to various anticancer drugs. Seven of the eight patients in the current study successfully resumed the desired anticancer drug regimen without standard desensitisation. No safety issues from omalizumab were observed.

Keyphrases

drug induced
end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
adverse drug
emergency department
patient reported outcomes